The Drugs for Neglected Diseases initiative (DNDi) is pleased to announce financial support from the Swiss Government to the DNDi-WHO joint initiative Global Antibiotic Research & Development Partnership (GARDP) launched earlier this year.
The Swiss Federal Office of Public Health will grant CHF 360’000 to support the start-up phase of GARDP whose mission is to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all in need. This funding will allow GARDP to build further its scientific strategy, and to prioritize and to launch the first R&D projects.
‘”After yesterday’s political declaration at the UN High-Level Meeting on AMR and the strong acknowledgment that governments must mobilize new funding to fight antimicrobial resistance, Switzerland is taking concrete action in this direction.” explains Dr Manica Balasegaram, Director of GARDP. “We are grateful for their support to our partnership’s efforts to boost the development of an R&D pipeline by using existing drugs and looking for new ones in ways that others will not.”
At its launch in May 2016, GARDP had secured seed funding from four governments – the Federal Ministry of Health of Germany, the Netherlands’ Ministry of Health Welfare and Sports, the South African Medical Research Council, and the United Kingdom Department for International Development – as well as from the medical humanitarian organization Médecins Sans Frontières, totalling over EUR 2 million for the incubation phase of two years.
More information on GARDP:
Tel: +41 22 906 92 47
Mob: +41 79 424 14 74